ALBANY, N.Y. - (Business Wire) AMRI (NASDAQ: AMRI) announced today that a second compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE: BMY) will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results